Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Oncoclinicas do Brasil Servicos Medicos (ONCO3.SA)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (R$) Price Target (R$) Rating
2021-09-0618.59-No Rating
2021-09-1615.4524.00Buy
2022-02-0310.7617.00Buy
2022-08-035.318.00Buy
2022-08-115.74-No Rating
2022-08-165.908.00Buy
2022-11-217.2310.00Buy
2023-05-029.03-No Rating
2024-10-284.625.70Neutral

Disclosures

  • UBS has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
  • Within the past 12 months, UBS has received compensation for investment banking services from this company/entity or one of its affiliates.
  • UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
  • Because this security exhibits higher-than-average volatility, the FSR has been set at 15% above the MRA for a Buy rating, and at -15% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.